EUVIMEDEUVIMED entdecken
Fallbericht

Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report

Takuya Araki, Akiko Kaneta, Hisashi Takei, Nobuhiko Kobayashi, Hideaki Yashima, Junko Tsukamoto, Yuri Miyazawa, Yoshiyuki Ogawa, Hiroshi Handa, Koujirou Yamamoto

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04812-6 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Takuya Araki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, J…. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Pyrimidines, Plasma Exchange, Protein Kinase Inhibitors. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, is used to treat lymphoplasmacytic lymphoma (LPL). A hallmark complication of LPL is hyperviscosity syndrome (HVS), caused by markedly elevated serum IgM levels. Plasma exchange (PE) is a standard treatment for HVS but may also remove circulating drugs, particularly those with high protein binding, potentially reducing drug exposure and efficacy. Evaluating the impact of PE on the pharmacokinetics of drugs used to treat LPL is important for optimal treatment. METHODS: We report the case of a 63-year-old man with LPL who presented with acute headache and was diagnosed with HVS. Tirabrutinib (480 mg, once daily) was initiated, and PE was performed the next day because of persistent IgM elevation. To assess the impact of PE on tirabrutinib plasma concentrations, blood samples were collected approximately 3 h prior to PE (C15), immediately before PE (C18), and immediately after PE (C20). RESULTS: The concentrations at C15, C18 and C20 were 33.3, 16.9, and 11.4 ng/mL, respectively. The elimination rate constant (ke) was calculated as 0.226 h⁻¹ before PE and 0.197 h⁻¹ during PE. Based on the pre-PE ke, the predicted post-PE concentration (C20) assuming no PE was approximately 10.6 ng/mL, slightly lower than the observed value. CONCLUSION: PE appeared to have minimal impact on the tirabrutinib plasma concentration, likely due to its large volume of distribution. Although further cases are needed, this case supports the feasibility of concomitant PE during tirabrutinib therapy without significant compromise of drug efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaPyrimidinesPlasma ExchangeProtein Kinase InhibitorsQuinazolinesHumansMaleMiddle AgedImmunoglobulin MImidazoles

Stichwörter der Autor:innen

Lymphoplasmacytic lymphomaPlasma concentrationPlasma exchangeTirabrutinib

Substanzen

PyrimidinestirabrutinibProtein Kinase InhibitorsQuinazolinesImmunoglobulin MImidazoles

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan. tkyaraki@gunma-u.ac.jp.
  • Department of Pharmacy, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, 371-8511, Gunma, Japan. tkyaraki@gunma-u.ac.jp.
  • Department of Pharmacy, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
  • Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
  • Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
  • Division of Blood Transfusion, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, 371-8511, Gunma, Japan.

Zitieren

APA

Araki, T., Kaneta, A., Takei, H., Kobayashi, N., Yashima, H., Tsukamoto, J., Miyazawa, Y., Ogawa, Y., Handa, H., & Yamamoto, K. (2025). Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04812-6

Vancouver

Araki T, Kaneta A, Takei H, Kobayashi N, Yashima H, Tsukamoto J, et al. Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04812-6

BibTeX
@article{Araki2025,
  author = {Araki, Takuya and Kaneta, Akiko and Takei, Hisashi and Kobayashi, Nobuhiko and Yashima, Hideaki and Tsukamoto, Junko and Miyazawa, Yuri and Ogawa, Yoshiyuki and Handa, Hiroshi and Yamamoto, Koujirou},
  title = {Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04812-6}
}
Kostenlos starten →